Yan-Ling Zhang is director of in vitro pharmacology in the Therapeutics Platform at the Broad Institute of MIT and Harvard. In this role, Zhang focuses on the development of biologically relevant high-throughput biochemical and phenotypic assays to enable high-throughput screening (HTS) for a variety of drug targets for psychiatric disorders. She is currently interested in developing a high-throughput calcium dynamics assay to monitor synaptic networks. Trained as an enzymologist, Zhang has expertise in inhibition kinetics and mechanism of action studies for HTS hits and lead compounds.
Before joining the Broad, Zhang led an enzymology group for assay development and hit validation at Wyeth Research from 2001 to 2007. She also helped build the biophysical capabilities for lead compound characterization at Merck Research Laboratories in Boston from 2007 to 2009.
Zhang received a bachelor’s degree in radiochemistry from Lanzhou University, a master’s degree in nuclear chemistry from China Institute of Atomic Energy, and a Ph.D. in biochemistry/enzymology from Institute of Biophysics of the Chinese Academy of Sciences. She completed postdoctoral work in enzyme structure and function at Michigan State University and Albert Einstein College of Medicine.
Contact Yan-Ling Zhang via email at firstname.lastname@example.org.Select Publications
Wagner F, Zhang YL, Fass DM et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chem. Sci. 2015; 6, 804–815.
Olson DE, Sleiman SF, Bourassa MW et al. Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism. Chem. Biol. 2015; 22(4), 439-445.